ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP6-18 Updated Commercial PA Request Form and PA List for Early Intensive Behavioral Intervention Services
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 17, 2018
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 2901 - 2910 လၢ 3159 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP5-18 Quality Initiatives at Blue Cross
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 16, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP4-18 Remember to Request Subscriber ID Cards
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 16, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P2-18 New Medical Drug PA Requirements for Voretigene Neparvovec (Luxturna)
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 11, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P1-18 New Drugs, Aimovig (erenumab), Fremanezumab and Galcanezumab Will Require PA
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 09, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP3-18 Pharmacy Benefit Update - Helixate FS Will No Longer Be Covered
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 08, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP2-18 Pharmacy Benefit Exclusion for Luxturna
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 08, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP1-18 Transition of Care Management Features for New Medicare Advantage Prescription Drug Plans
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 08, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2017 December Provider Press
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 29, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P82-17 Commercial Prior Authorization Requirement for Outpatient Services for Occupational Therapy, Physical Therapy and Speech Therapy
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 13, 2017